Objective:This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer.Methods:the databases of VIP,CNKI,WanFang,CBM,Pub Med,...Objective:This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer.Methods:the databases of VIP,CNKI,WanFang,CBM,Pub Med,Cochrane Library and EMBASE were searched to collect the randomized controlled trials(RCTs)of Kang-ai injection,combined with chemotherapy versus chemotherapy alone for the treatment of ovarian cancer.The retrieval time was from the database setup to December 20,2018.After two researchers independently screened the researches,extracted data and evaluated the risk of the included studies,the RevMan 5.3 software was used for analysis.A total of 8 RCTS were included.Results:Results showed that patients in Kang-ai injection combined with chemotherapy group were superior to the conventional chemotherapy group patients in total effective rate[RR=1.31,95%CI(1.11,1.54),P=0.001],quality of life[RR=1.69,95%CI(1.35,2.13),P<0.001],leukopenia[RR=0.63,95%CI(0.51,0.77),P<0.001],nausea and vomiting[RR=0.41,95%CI(0.24,0.70),P=0.001],decreased hemoglobin[RR=0.50,95%CI(0.28,0.88),P=0.002],and thrombocytopenia[RR=0.45,95%CI(0.24,0.85),P=0.01].Conclusion:Kang-ai injection combined with chemotherapy for ovarian cancer is better than chemotherapy alone in improving total effective rate and quality of life,reducing the incidence of adverse reactions.Limited by the number and quality of included studies,the above conclusions are yet to be verified by more high-quality studies.展开更多
Objective:To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection(KAI)in gastric cancer cells.Methods:Gastric cancer cell lines MGC803 and BGC823 were treated by ...Objective:To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection(KAI)in gastric cancer cells.Methods:Gastric cancer cell lines MGC803 and BGC823 were treated by 0,0.3%,1%,3%and 10%KAI for 24,48 and 72 h,respectively.The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide(MTT)assay.The apoptosis and cell cycle were evaluated by flow cytometry.Interleukin(IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction(qRT-PCR)and enzyme-linked immune sorbent assay(ELISA),respectively.The protein expression levels of cyclin A,cyclin E,cyclin B1,cyclin D1,p21,retinoblastoma(RB),protein kinase B(AKT),extracellular regulated protein kinases(ERK),signal transducer and activator of transcription(STAT)1 and STAT3 were detected by Western blot.Results:KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose-and time-dependent manner.After treated with KAI for 48 h,the proportion of G,phase was increased,expression level of cyclin D1 and phosphorylation-RB were down-regulated,whereas the expression of p21 was up-regulated(all P<0.01).Furthermore,48-h treatment with KAI decreased the phosphorylation level of STAT3,inhibited the mRNA and protein expressions of IL-6(all P<0.01).IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3%and 10%KAI,and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level(all P<0.01).Conclusion:KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G_(1)phase arrest in gastric cancer cells.展开更多
文摘Objective:This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer.Methods:the databases of VIP,CNKI,WanFang,CBM,Pub Med,Cochrane Library and EMBASE were searched to collect the randomized controlled trials(RCTs)of Kang-ai injection,combined with chemotherapy versus chemotherapy alone for the treatment of ovarian cancer.The retrieval time was from the database setup to December 20,2018.After two researchers independently screened the researches,extracted data and evaluated the risk of the included studies,the RevMan 5.3 software was used for analysis.A total of 8 RCTS were included.Results:Results showed that patients in Kang-ai injection combined with chemotherapy group were superior to the conventional chemotherapy group patients in total effective rate[RR=1.31,95%CI(1.11,1.54),P=0.001],quality of life[RR=1.69,95%CI(1.35,2.13),P<0.001],leukopenia[RR=0.63,95%CI(0.51,0.77),P<0.001],nausea and vomiting[RR=0.41,95%CI(0.24,0.70),P=0.001],decreased hemoglobin[RR=0.50,95%CI(0.28,0.88),P=0.002],and thrombocytopenia[RR=0.45,95%CI(0.24,0.85),P=0.01].Conclusion:Kang-ai injection combined with chemotherapy for ovarian cancer is better than chemotherapy alone in improving total effective rate and quality of life,reducing the incidence of adverse reactions.Limited by the number and quality of included studies,the above conclusions are yet to be verified by more high-quality studies.
基金Supported by National Science and Technology Major Project of the Ministry of Science and Technology of China(No.2017ZX09304025)Construction Program of Clinical Cooperation Ability of Chinese and Western Medicine for Major and Difficult Diseases(No.2019-163)+2 种基金the Key Research and Development Program of Liaoning Province(No.2018225060)Science and Technology Plan Project of Liaoning Province(No.2016007010)Science and Technology Plan Project of Shenyang City(No.19-112-4-099)。
文摘Objective:To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection(KAI)in gastric cancer cells.Methods:Gastric cancer cell lines MGC803 and BGC823 were treated by 0,0.3%,1%,3%and 10%KAI for 24,48 and 72 h,respectively.The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide(MTT)assay.The apoptosis and cell cycle were evaluated by flow cytometry.Interleukin(IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction(qRT-PCR)and enzyme-linked immune sorbent assay(ELISA),respectively.The protein expression levels of cyclin A,cyclin E,cyclin B1,cyclin D1,p21,retinoblastoma(RB),protein kinase B(AKT),extracellular regulated protein kinases(ERK),signal transducer and activator of transcription(STAT)1 and STAT3 were detected by Western blot.Results:KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose-and time-dependent manner.After treated with KAI for 48 h,the proportion of G,phase was increased,expression level of cyclin D1 and phosphorylation-RB were down-regulated,whereas the expression of p21 was up-regulated(all P<0.01).Furthermore,48-h treatment with KAI decreased the phosphorylation level of STAT3,inhibited the mRNA and protein expressions of IL-6(all P<0.01).IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3%and 10%KAI,and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level(all P<0.01).Conclusion:KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G_(1)phase arrest in gastric cancer cells.
文摘目的:收集2014年12月之前国内国外发表的关于康艾注射液姑息治疗晚期恶性肿瘤的随机对照试验文献,利用系统评价的方法评价康艾注射液在晚期恶性肿瘤姑息治疗中的疗效和安全性。方法:全面检索MEDLINE(Pubmed)、Cochrane library、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP)、中国期刊全文数据库(CNKI)、万方数据库以得到康艾注射液姑息治疗晚期恶性肿瘤的合适文献,并采用Cochrane协作网提供的Rev Man 5.2软件对数据进行处理。结果:共纳入8个RCT,545例,文献质量均较低。对KPS评分改善情况进行meta分析,异质性检验(χ2=12.12,P=0.06,I2=51%),采用随机效应模型统计分析,治疗组优于对照组(RR=2.69,Z=4.54,P<0.000 01,95%CI=[1.75,4.12]);采用描述性统计方法分析,改善纳差症状方面共有4个研究,其中3个研究提示治疗组优于对照组。减轻疼痛方面共纳入6个试验,其中4个试验提示康艾注射液有利于减轻癌痛。康艾注射液姑息治疗在改善乏力症状和改善睡眠方面,结果均提示优于对照组。结论:康艾注射液在姑息治疗晚期恶性肿瘤方面,能够改善患者纳差、癌痛、乏力、失眠不适症状,并提高患者生活质量,但因纳入文献质量较低,需要更多更规范的RCT予以进一步印证。
文摘目的:定量分析康艾注射液联合化疗治疗急性白血病的疗效和安全性。方法:计算机检索Cochrane Library、Pubmed、EMBASE、Cancer Lit、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库,检索时间从各数据库建库至2015年4月30日,纳入康艾注射液联合化疗方案治疗急性白血病的随机对照试验(RCT),并用Rev Man 5.3软件对数据进行统计分析,运用GRADE方法对各结局指标包含的证据体进行证据质量分级。结果:共纳入5篇RCT,Meta分析结果显示,与单纯化疗比较,康艾注射液联合化疗方案可提高完全缓解率(OR=2.05,95%CI:1.04-4.03,P=0.04),降低化疗后骨髓抑制发生率(OR=0.44,95%CI:0.21-0.94,P=0.03),二者在感染发生率(OR=0.72,95%CI:0.19-2.82,P=0.64)和全因病死率(OR=0.24,95%CI:0.01-6.19,P=0.39)方面差异无统计学意义。结论:康艾注射液联合化疗方案在治疗急性白血病方面优于单纯化疗。
